RxDoctor Payments Data

Jamie Garonzik, PA

Physician Assistant · Ellicott City, MDNPI 1710422688

Payments from drug & device makers

$3,463in general payments, 2019–2025

Across 143 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$521
  • Esperion Therapeutics, Inc.$291
  • Novartis$241
  • Novo Nordisk$232
  • Lilly USA, LLC$220
  • Amgen$198
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$3,463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,463 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$52,989
Medicare patients
214
Services billed
1,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$29,790
EliquisApixaban20$17,833
JardianceEmpagliflozin11$13,524
XyostedTestosterone Enanthate14$12,233
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,213
PaxlovidNirmatrelvir/Ritonavir19$4,206
Olmesartan Medoxomil59$2,864
Rosuvastatin Calcium118$2,750
Trimipramine Maleate13$1,934
Celecoxib11$1,180
Liothyronine Sodium19$1,097
Bupropion XlBupropion Hcl17$888
FenofibrateFenofibrate,micronized26$821
Atorvastatin Calcium64$669
Methylphenidate Hcl16$613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$232$29,79024 claims
PfizerEliquis, Paxlovid$194$22,03939 claims
Boehringer IngelheimJardiance$28$13,52411 claims
Antares Pharma, Inc.Xyosted$75$12,23314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Ellicott City

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →